Showing 4131-4140 of 10630 results for "".
- AAD Pediatric Guidelines Give Strong Backing to Roflumilast Creamhttps://practicaldermatology.com/news/aad-pediatric-guidelines-give-strong-backing-to-roflumilast-cream/2486794/Arcutis Biotherapeutics announced that ZORYVE (roflumilast) cream has received a strong recommendation in the American Academy of Dermatology (AAD) clinical practice guidelines for pediatric atopic dermatitis (AD), marking inclusion in the organization’s first guid
- Acquisition Broadens Newmedical’s Scar Care and Skincare Platformhttps://practicaldermatology.com/news/strategic-acquisition-broadens-newmedicals-scar-care-and-skincare-platform/2486628/Newmedical Technology, Inc. announced its acquisition of Derma Made®, marking a strategic expansion of its dermatology and aesthetics portfolio, according to a news release from the company. The transaction will meld Newmedica
- Simvastatin Shows Promise as Adjunct Treatment for Vitiligo in Meta-Analysishttps://practicaldermatology.com/news/simvastatin-shows-promise-as-adjunct-treatment-for-vitiligo-in-meta-analysis/2474442/A new meta-analysis highlights the therapeutic potential of simvastatin for vitiligo, showing significant benefits in repigmentation and disease severity reduction. Vitiligo, an autoimmune disorder marked by melanocyte destruc
- Scientists 3D-print Hair Follicles in Lab-grown Skinhttps://practicaldermatology.com/news/scientists-3d-print-hair-follicles-in-lab-grown-skin/2462137/Scientists at Rensselaer Polytechnic Institute have 3D-printed hair follicles in human skin tissue cultured in the lab. This marks the first time that researchers have used the technology to generate hair follicles. The findings appear in
- VelaShape III Platform from Syneron Receives FDA Clearance for Abdominal Circumferential Reductionhttps://practicaldermatology.com/news/20130911-synerons_velashape_iii_platform_receives_fda_clearance_for_abdominal_circumferential_reduction/2459464/The VelaShape III, Syneron's new non-invasive body shaping platform, recently received FDA clearance and CE mark approval for temporary reduction in circumference of the abdomen. The VelaShape III
- NYC PrideFest: Galderma Aesthetics to Participatehttps://practicaldermatology.com/news/nyc-pridefest-galderma-aesthetics-to-participate/2461249/Galderma is participating in New York City's official LGBTQIA+ Pride (NYC Pride) event. This month marks the official launch of Restylane's "XpresYourself" communications campaign, which gives a nod to Restylane's XpresHAn Technology™, a u
- Bio-Oil Celebrates Body Confidence Through Body Positivity Month Campaignhttps://practicaldermatology.com/news/bio-oil-celebrates-body-confidence-through-body-positivity-month-campaign/2461538/Bio-Oil is rolling out a month-long campaign in celebration of February's Body Positivity Month to encourage self-love, promote body confidence, and highlight the role that Bio-Oil plays in helping people to love their stretch marks due to pregnancy, to scars from surgical procedur
- FDA Approves Expanded Indication for Merck's Keytruda for Treatment of Advanced Melanomahttps://practicaldermatology.com/news/fda-approves-expanded-indication-for-mercks-keytruda-for-treatment-of-advanced-melanoma/2458773/The FDA has approved an expanded indication for Merck’s Keytruda® (pembrolizumab), an anti-PD-1 (programmed death receptor-1) therapy, to include the first-line treatment of patients with unresectable or metastatic melanoma. This approval marks the second FDA-approved indicat
- Xylyx Bio's Matrikynes Improves the Structure, Function, and Appearance of Skinhttps://practicaldermatology.com/news/xylyx-bios-matrikynes-improves-the-structure-function-and-appearance-of-skin/2461645/Xylyx Bio’s
- Aditxt, Inc. Successfully Completes Preclinical Toxicity Study of Its Psoriasis Drug Candidate ADI-100https://practicaldermatology.com/news/aditxt-inc-successfully-completes-preclinical-toxicity-study-of-its-psoriasis-drug-candidate-adi-100/2461260/Aditxt, Inc.’s